WO2009095931A2 - An efficient process to induce enantioselectivity in procarbonyl compounds - Google Patents

An efficient process to induce enantioselectivity in procarbonyl compounds Download PDF

Info

Publication number
WO2009095931A2
WO2009095931A2 PCT/IN2008/000476 IN2008000476W WO2009095931A2 WO 2009095931 A2 WO2009095931 A2 WO 2009095931A2 IN 2008000476 W IN2008000476 W IN 2008000476W WO 2009095931 A2 WO2009095931 A2 WO 2009095931A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
chiral
metal
complex
nhconh
Prior art date
Application number
PCT/IN2008/000476
Other languages
French (fr)
Other versions
WO2009095931A3 (en
Inventor
Bollu Ravindra Babu
Chava Satya Narayana
Original Assignee
Aptuit Laurus Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptuit Laurus Pvt Ltd filed Critical Aptuit Laurus Pvt Ltd
Priority to US12/667,985 priority Critical patent/US9156756B2/en
Priority to PL08808147T priority patent/PL2235023T3/en
Priority to EP08808147.6A priority patent/EP2235023B1/en
Priority to DK08808147.6T priority patent/DK2235023T3/en
Priority to SI200831165T priority patent/SI2235023T1/en
Priority to ES08808147.6T priority patent/ES2449754T3/en
Publication of WO2009095931A2 publication Critical patent/WO2009095931A2/en
Publication of WO2009095931A3 publication Critical patent/WO2009095931A3/en
Priority to US13/531,011 priority patent/US9073817B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/36—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal
    • C07C29/38—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones
    • C07C29/42—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring increasing the number of carbon atoms by reactions with formation of hydroxy groups, which may occur via intermediates being derivatives of hydroxy, e.g. O-metal by reaction with aldehydes or ketones with compounds containing triple carbon-to-carbon bonds, e.g. with metal-alkynes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • C07F3/003—Compounds containing elements of Groups 2 or 12 of the Periodic Table without C-Metal linkages

Definitions

  • Present invention is directed towards the cost effective and industrially applicable process to induce enantioselectivity with improved yields.
  • the present invention is also describes an improved process for making organometallic complexes.
  • Asymmetric addition of organometallic compounds to carbonyls is a useful method for the production of chiral secondary/tertiary-alcohols.
  • the active catalyst is generated in situ by the reaction of Lewis acid with chiral ligands.
  • Addition of organometallic reagents to aldehydes and activated ketones has been achieved with excellent enantioselectivity. With inactivated ketones there has been some success, e.g., using salen 1 and camphanosulphonamide ligand 2.
  • employing these promoters chiral alcohols has been obtained in high yields and ee upto 99%, they have limited applicability in industrial scale synthesis of the pharmaceutical intermediates, because they are expensive, difficult to store, difficult to handle, especially dialkyl zinc's are highly pyrophoric and require special modification to transfer the reagent.
  • the main object of the present invention is to provide an improved process to make organometallic complexes using metal halides
  • Another object of the present invention is to provide a process to induce the enantioselectivity in proketones.
  • Another object of the present invention is to provide a process to prepare an amino alcohol of formula
  • Another object of the present invention is to provide an improved process to prepare organometallic complex without using Dialkyl zinc.
  • the main object is to prepare organometallic complex comprising the steps of;
  • metal salts of chiral and achiral additives are prepared by treating the chiral and/or achiral additives with a base selected from metal hydrides, metal alkoxides or metal hydroxides or organic bases such as DBU, HMDS, lower alkyl amines etc, and metal hydrides are more preferred.
  • metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
  • Grignard reagent is selected from alkyl, alkenyl, alkynyl and aryl magnesium halides.
  • R 1 is
  • CON(C 1 -C 6 -alkyl) 2 NHCONH 2 , NHCONH(Ci -C 6 -alkyl), NHCON(Ci -C 6 -alkyl) 2 , CO 2 -Ci -C 6 -alkyl, C 3 -C 7 -cycloalkyl, or C 1 -C 6 -alkoxy; phenyl, biphenyl, or naphthyl, unsubstituted or substituted with one to four substituent selected from R 3 , R 4 , R 5 , and R 6 ; R 3 , R 4 , R 5 , and R 6 are independently: halo (Cl, Br 5 F, I) 5 CF 3 , CN 5 NO 2 , NH 2 , NH(C 1 -
  • C 6 -alkyl N(C 1 -C 6 -alkyl) 2 , CONH 2 , CONH(Cj -C 6 -alkyl), CON(C 1 -C 6 -alkyl) 2 , NHCONH 2 , NHCONH(C 1 -C 6 -alkyl), NHCON(Ci -C 6 -alkyl) 2 , aryl, CO 2 -C 1 -C 6 - alkyl, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, or Ci -C 6 - alkoxy, such that C 1 -C 6 -alkyl is unsubstituted or substituted with aryl, aryl is defined as phenyl, biphenyl, or naphthyl, unsubstituted or substituted with C 1 -
  • R 2 is: H C 1 -C 6 -alkyl, C 2 -C 6 - alkenyl, or C 2 -C 6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF 3 , CN 5 NO 2 , NH 25 NH(Ci -C 6 -alkyl), N(Ci -C 6 -alkyl) 2 , CONH 2 , CONH(Cj -C 6 -alkyl), CON(Ci -C 6 -alkyl) 2 , NHCONH 2 , NHCONH(Ci -C 6 -alkyl), NHCON(Ci -C 6 -alkyl) 2 , CO 2 --Ci -C 6 -alkyl, C 3 -C 7 -cycloalkyl, or Ci -C 6 -alkoxy;
  • R is:
  • salts of chiral and achiral additives are prepared by treating the chiral and achiral additives with metal hydride or metal alkoxides or metal hydroxides or organic bases whereas metal hydrides are more preferred.
  • metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
  • Grignard reagent is selected from alkyl, alkenyl, alkynyl and aryl magnesium halides.
  • Lithium/Zinc reagent is selected from alkyl, alkenyl, alkynyl and aryl Lithium/Zinc reagents.
  • R 3 is halo (Cl, Br, F 8 1)
  • R 1 is amino or substituted amino
  • R 2 is C 1 -C 6 -allcyl, C 2 -C 6 -alkenyl, or C2 -C 6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF 3 , CN, NO 2 , NH 25 NH(C 1 -C 6 -allcyl), N(C 1 -C 6 -alkyl) 2 , CONH 2 , CONH(C 1 -C 6 -alkyl), CON(Ci -C 6 -alkyl) 2 , NHCONH 2 , NHCONH(Ci -C 6 -alkyl), NHCON (C, -C 6 -alkyl) 2 , CO 2 -Ci -C 6 -alkyl
  • organometallic reagent of formula R 2 M wherein M represents Li, Zn or MgX; X is Cl 9 Br, I and F; to the metal complex to get an organometal complex • Mixing a carbonyl compound with the organometal complex to give the chiral alcohol.
  • metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
  • the base is selected from metal hydrides, metal alkoxides, metal hydroxides and organic bases.
  • the compounds of the present invention have asymmetric centers and this invention includes all of the optical isomers and mixtures thereof. Examples:
  • Example -1 Preparation of (S)-5-Chloro-oi-(cyclopropylethynylV2-amino- ⁇ - ftrifluoromethyD benzene methanol.
  • a solution of chloromagnesiurn-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (3.62 g, 54.7 mmol) to a stirred solution of rc-butyl magnesium chloride (2M solution in THF, 26.8 ml, 53.7 mmol) at 0-5 0 C. The solution was stirred for another 2h at 0-5 °C. In another dry flask, to anhydrous THF (80 ml) at 0-5 0 C 5 NaH (57% dispersion in mineral oil, 4.71 g, 117.7 mmol) was added slowly.
  • CPA-MgCl chloromagnesiurn-cyclopropylacetylide
  • reaction mixture was quenched with 30% aq K 2 CO 3 (5.5 ml) and aged for Ih.
  • the solid material was filtered and washed with THF (5 x 10 ml).
  • the combined filtrate concentrated to approx 10 ml under reduced pressure, toluene (100 ml) was added and sequentially washed with 30% citric acid (2 x 50 ml) and water (50 ml).
  • the combined aqueous layer was back- extracted with toluene (25 ml) and saved for pyrrolidinyl norephidrine recovery.
  • the combined organic phase was concentrated to approx 10 ml and hexane (50 ml) was added slowly with stirring.
  • Example -2 Preparation of ffl-5-Chloro- ⁇ -rcyclopropylethynyl)-2-amino- ⁇ -(trifluoromethyl) benzene methanol hydrochloride
  • a solution of chloromagnesium-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (3.62 g, 54.7 mmol) to a stirred solution of «-butyl magnesium chloride (2M solution in THF, 26.8 ml, 53.7 mmol) at 0-5 "C. The solution was stirred for another 2h at 0-5 0 C. In another dry flask, to anhydrous THF (80 ml) at 0-5 °C, NaH (57% dispersion in mineral oil, 4.71 g, 117.7 mmol) was added slowly.
  • CPA-MgCl chloromagnesium-cyclopropylacetylide
  • the reaction mixture was quenched with 30% aq K 2 CO 3 (5.5 ml) and aged for Ih.
  • the solid material was filtered and washed with THF (5 x 10 ' ml).
  • the combined filtrate concentrated completely under reduced pressure.
  • the residue was dissolved in isopropyl acetate (100 ml) and sequentially washed with 30% citric acid (2 x 50 ml) and water (50 ml).
  • the combined aqueous layer was back-extracted with IPAc (25 ml) and saved for pyrrolidinylnorephidrine recovery.
  • To the combined organic phase was added 12N HCl (4.1 ml).
  • the resulting mixture was aged at 25-30 0 C and then dried azeotropically and flushed with IPAc (2 x 25 ml).
  • the slurry was aged for another 24 h at 25-30 0 C and then filtered and washing was performed with cold IPAc (3 x 10 ml) and dried to afford 10 g of analytically pure (5>5-Chloro- ⁇ - (cyclopropylethynyl)-2-amino- ⁇ -(trifluoromethyl) benzene methanol hydrochloride as a white solid.
  • Example -3 Preparation of ⁇ fi)-5-Chloro- ⁇ -(cyclopropylethynylV2-ammo- ⁇ - (trifluoromethyP benzene methanol.
  • a solution of chloromagnesium-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (36.2 g, 0.548 mol) to a stirred solution of «-butyl magnesium chloride (2M solution in THF, 268.0 ml, 0.535 mol) at 0-5 0 C. The solution was stirred for another 2h at 0-5 °C. In another dry flask, to anhydrous THF (300 ml) at 0-5 0 C, NaH (57% dispersion in mineral oil, (44.0 g, 0.916 mol) was added slowly.
  • CPA-MgCl chloromagnesium-cyclopropylacetylide
  • reaction mixture was diluted with toluene (300ml) and stirred for Ih and quenched into IM citric acid solution (1000ml) and stirred for 10 min.
  • Toluene layer was separated and washed with water (2X500ml). The toluene layer was concentrated completely to give residue.
  • the obtained residue was dissolved in methanol (300ml) and isolated by adding DM water (450ml).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

An efficient method to induce the enantioselectivity in procarbonyl compounds using chiral organometallic complexes. The present invention is also described a method for producing organo metallic complexes using a base and a metal halide.

Description

"An efficient process to induce enantioselectivity in procarbonyl compounds"
Field of invention:
Present invention is directed towards the cost effective and industrially applicable process to induce enantioselectivity with improved yields. The present invention is also describes an improved process for making organometallic complexes.
Background of the invention:
Asymmetric addition of organometallic compounds to carbonyls is a useful method for the production of chiral secondary/tertiary-alcohols. Typically for asymmetric synthesis, the active catalyst is generated in situ by the reaction of Lewis acid with chiral ligands. Addition of organometallic reagents to aldehydes and activated ketones has been achieved with excellent enantioselectivity. With inactivated ketones there has been some success, e.g., using salen 1 and camphanosulphonamide ligand 2.
Figure imgf000002_0001
1 2
Generally, stoichiometric amount of the promoters [Lewis acid, e.g., ZnR2 (R = alkyl/aryl), Zn(OTf)2, Cu(OTf)2, etc] is required for these asymmetric syntheses. Although, employing these promoters chiral alcohols has been obtained in high yields and ee upto 99%, they have limited applicability in industrial scale synthesis of the pharmaceutical intermediates, because they are expensive, difficult to store, difficult to handle, especially dialkyl zinc's are highly pyrophoric and require special modification to transfer the reagent. Moreover the liberated byproduct methane/ethane (when using ZnMe2/ ZnEt2) .are a concern on industrial scale synthesis. To overcome this problem, herein we report an efficient synthesis of active organometallic catalyst formed in situ from chiral auxiliaries and Metal halides. For example ephedrine zincate 3 was obtained by first deprotonation of alcohol (achiral auxiliary) and N-pyrollidene noreph drine (chiral auxiliary) with a base (e.g. NaH); to the resulting alkoxides was added zinc halides (scheme IA). The advantages include the low cost of zinc halides, ease of storing, handling and transfer. Moreover, the byproduct (sodium halides) formed has no safety issues, Based upon this concept, other active catalysts were synthesized using chiral ligands (such as binols, amino alcohols, amino alcohol derivatives, ethylenediamine, alkylated ethylene diamines and ethylenediamine derivatives in combination with metal source based on zinc and copper (scheme 1).
Scheme-1
Figure imgf000003_0001
Scheme-1 A
Figure imgf000003_0002
Using these chiral catalysts alkylation/alkynation of aldehydes afforded corresponding secondary alcohols (scheme-2),
Scheme-2
RMgX; when
(R = alkyl/termiπal alkyne) > R1CHC) or 1H
. RH/base; when (R = terminal alkyne) while addition to ketones/β-ketoesters afforded corresponding tertiary alcohols (scheme 3A and 3B).
Scheme-3A
Figure imgf000004_0001
Scheme-3B
Figure imgf000004_0002
Summary of the invention: The main object of the present invention is to provide an improved process to make organometallic complexes using metal halides
Another object of the present invention is to provide a process to induce the enantioselectivity in proketones.
Another object of the present invention is to provide a process to prepare an amino alcohol of formula
Figure imgf000004_0003
by the addition of (un) substituted alkane/alkyne (R2) to a ketone using an organometallic complex Another object of the present invention is to provide an improved process to prepare organometallic complex without using Dialkyl zinc.
Detailed description of the invention:
In accordance with the present invention the main object is to prepare organometallic complex comprising the steps of;
• Preparing the salts of chiral and/or achiral additives • Adding metal halide to the above obtained salts and converting to chiral and/or achiral metal complex
• Adding Grignard reagent/lithium reagent or Zinc reagent etc, to the above chiral and/or achiral metal complex to form chiral organometal complex.
(or) • Adding terminal alkyne and a base to the above chiral metal complex to form chiral organometal complex.
The process as described above wherein metal salts of chiral and achiral additives are prepared by treating the chiral and/or achiral additives with a base selected from metal hydrides, metal alkoxides or metal hydroxides or organic bases such as DBU, HMDS, lower alkyl amines etc, and metal hydrides are more preferred.
The process as described above wherein the metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
The process as described above wherein the Grignard reagent is selected from alkyl, alkenyl, alkynyl and aryl magnesium halides.
In a specific embodiment of the present invention is to provide an efficient method to induce the enantioselectivity in procarbonyl compounds and their enantiomers which are shown below;
Figure imgf000006_0001
Wherein R1 is
C1 -C6 -alkyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN, NO2, NH2, NH(Ci -C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(Ci -C6 --alkyl),
CON(C1 -C6 -alkyl)2, NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON(Ci -C6 -alkyl)2, CO2 -Ci -C6 -alkyl, C3 -C7 -cycloalkyl, or C1 -C6 -alkoxy; phenyl, biphenyl, or naphthyl, unsubstituted or substituted with one to four substituent selected from R3, R4, R5, and R6 ; R3, R4, R5, and R6 are independently: halo (Cl, Br5 F, I)5 CF3, CN5 NO2, NH2, NH(C1 -
C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(Cj -C6 -alkyl), CON(C1 -C6 -alkyl)2, NHCONH2, NHCONH(C1 -C6 -alkyl), NHCON(Ci -C6 -alkyl)2, aryl, CO2 -C1 -C6 - alkyl, C1 -C6 -alkyl, C2 -C6 -alkenyl, C2 -C6 -alkynyl, C3 -C7 -cycloalkyl, or Ci -C6 - alkoxy, such that C1 -C6 -alkyl is unsubstituted or substituted with aryl, aryl is defined as phenyl, biphenyl, or naphthyl, unsubstituted or substituted with C1 -C6 -alkyl, Ci -C6
-alkoxy, NO2, or halo (Cl, Br5 F, I);
R2 is: H C1 -C6 -alkyl, C2 -C6 - alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN5 NO2, NH25 NH(Ci -C6 -alkyl), N(Ci -C6 -alkyl)2, CONH2, CONH(Cj -C6 -alkyl), CON(Ci -C6 -alkyl)2, NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON(Ci -C6 -alkyl)2, CO2 --Ci -C6 -alkyl, C3 -C7 -cycloalkyl, or Ci -C6 -alkoxy; a. C1 -C4 - perfluoroalkyl,
R is:
C1 -C6 -alkyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN, NO2, NH2, NH(Cj -C6 -alkyl), N(Ci -C6 -alkyl)2, CONH2, CONH(Ci -C6 -alkyl), CON(Ci -C6 -alkyl)2, NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON (C1 -C6 -alkyl)2, CO2 - C1 -C6 -alkyl, C3 -C7 -cycloalkyl, or C1 -C6 -alkoxy;
comprising the steps of: • Preparing the salts of chiral and/or achiral additives
• Adding metal halide to the above obtained salts and converting to chiral and/or achiral metal complex
• Adding the Grignard reagent/ lithium reagent or Zinc reagent etc, to the above chiral and/or achiral metal complex to form chiral organometal complex. • Adding the procarbonyl compounds to the chiral organometal complex
The process as described above wherein salts of chiral and achiral additives are prepared by treating the chiral and achiral additives with metal hydride or metal alkoxides or metal hydroxides or organic bases whereas metal hydrides are more preferred.
The process as described above wherein the metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
The process as described above wherein the Grignard reagent is selected from alkyl, alkenyl, alkynyl and aryl magnesium halides.
The process as described above wherein the Lithium/Zinc reagent is selected from alkyl, alkenyl, alkynyl and aryl Lithium/Zinc reagents.
A further embodiment of the invention is the process for the preparation of an amino alcohol of formula:
Figure imgf000007_0001
Wherein
R3 is halo (Cl, Br, F8 1) R1 is amino or substituted amino R2 is C1 -C6 -allcyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN, NO2, NH25 NH(C1 -C6 -allcyl), N(C1 -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl), CON(Ci -C6 -alkyl)2, NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON (C, -C6 -alkyl)2, CO2 -Ci -C6 -alkyl, C3 -C7 - cycloalkyl, or C1 -C6 -alkoxy;
comprising the steps of:
• Adding slowly an alkanol and chiral additive to a base in an organic solvent • Treating the above reaction mass with a metal halide to get chiral/achiral metal complex
• Adding organometallic reagent of formula R2M, wherein M represents Li, Zn or MgX; X is Cl9 Br, I and F; to the metal complex to get an organometal complex • Mixing a carbonyl compound with the organometal complex to give the chiral alcohol.
The process as described above wherein the chiral additive is pyrrolidinyl norephidrine or its enantiomer or diastereomer.
The process as described above wherein the metal halide is a transitional metal halide and the most preferred metal halides are being Zinc and copper halides.
The process as described above wherein the base is selected from metal hydrides, metal alkoxides, metal hydroxides and organic bases.
The process as described above wherein the preferred metal hydride is sodium hydride.
The compounds of the present invention have asymmetric centers and this invention includes all of the optical isomers and mixtures thereof. Examples:
The present invention will now be further explained in the following examples. However, the present invention should not be construed as limited thereby. One of ordinary skill in the art will understand how to vary the exemplified preparations to obtain the desired results.
Example -1: Preparation of (S)-5-Chloro-oi-(cyclopropylethynylV2-amino-α- ftrifluoromethyD benzene methanol.
Cyclopropyl acetylene Zinc bromide Sodium hydride [1R,2S]-N-pyrτolidinyl norephedrine
Figure imgf000009_0002
Figure imgf000009_0001
2,2,2-TrifluoroBlhaπol (S)-5-chloro-a-(cyclopropylethynyl)-
4-chloro-2-trifluoroacatyl aniline n-Bulyl magnesium chloride 2-amlno-a-(trifluoromethyl)banzena methanol
A solution of chloromagnesiurn-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (3.62 g, 54.7 mmol) to a stirred solution of rc-butyl magnesium chloride (2M solution in THF, 26.8 ml, 53.7 mmol) at 0-5 0C. The solution was stirred for another 2h at 0-5 °C. In another dry flask, to anhydrous THF (80 ml) at 0-5 0C5 NaH (57% dispersion in mineral oil, 4.71 g, 117.7 mmol) was added slowly. The ice-bath was removed and the contents stirred at ambient temp for 30 min and cooled again to 0-5 0C. 2,2,2- Trifluoroethanol (4.3g, 3.13 ml, 42.9 mmol), and (IR, 2S)-pyrrolidinyl norephidrine (13.5 g,
65.8 mmol) were added and the resulting pale yellow solution was stirred at ambient temp for
60 min. A solution of zinc bromide (11.98 g, 54 mmol) in THF (40 ml) was added and the suspension was stirred for 60 min at 25-30 °C. The solution of CPA-MgCl was then warmed to
25-30 "C and then transferred to the ephedrine zincate reagent by cannula, over 15 min., with THF (5 ml) as a wash, and the suspension was stirred for another 2h. 4-Chloro-2- trifluoroacetylaniline (10 g, 44.7 mmol) was added in one portion to the reaction mixture and stirred for 15h.
The reaction mixture was quenched with 30% aq K2CO3 (5.5 ml) and aged for Ih. The solid material was filtered and washed with THF (5 x 10 ml). The combined filtrate concentrated to approx 10 ml under reduced pressure, toluene (100 ml) was added and sequentially washed with 30% citric acid (2 x 50 ml) and water (50 ml). The combined aqueous layer was back- extracted with toluene (25 ml) and saved for pyrrolidinyl norephidrine recovery. The combined organic phase was concentrated to approx 10 ml and hexane (50 ml) was added slowly with stirring. The mixture was cooled to O0C, the solid was collected by filtration, washed with cold hexane (2 x 10 ml) and dried to give 10 g of pure (S)-5-Chloro-α-(cyclopropylethynyl)-2- amino-ct- (trifluoromethyl) benzene methanol as a white solid.
Example -2: Preparation of ffl-5-Chloro-α-rcyclopropylethynyl)-2-amino-α-(trifluoromethyl) benzene methanol hydrochloride
A solution of chloromagnesium-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (3.62 g, 54.7 mmol) to a stirred solution of «-butyl magnesium chloride (2M solution in THF, 26.8 ml, 53.7 mmol) at 0-5 "C. The solution was stirred for another 2h at 0-5 0C. In another dry flask, to anhydrous THF (80 ml) at 0-5 °C, NaH (57% dispersion in mineral oil, 4.71 g, 117.7 mmol) was added slowly. The ice-bath was removed and the contents stirred at ambient temp for 30 min and cooled again to 0-5 °C. 2,2,2- Trifluoroethanol (4.3g, 3.13 ml, 42.9 mmol), and (IR, 2S)-pyrrolidinylnorephidrine (13.5 g, 65.8 mmol) were added and the resulting pale yellow solution was stirred at ambient temp for 60 min. A solution of zinc bromide (11.98 g, 54 mmol) in THF (40 ml) was added and the suspension was stirred for 60 min at 25-30 °C. The solution of CPA-MgCl was then warmed to 25-30 0C and then transferred to the ephedrine zincate reagent by cannula, over 15 min., with THF (5 ml) as a wash, and the suspension was stirred for another 2h. 4-Chloro-2- trifluoroacetylaniline (10 g, 44.7 mmol) was added in one portion to the reaction mixture and stirred for 15h.
The reaction mixture was quenched with 30% aq K2CO3 (5.5 ml) and aged for Ih. The solid material was filtered and washed with THF (5 x 10' ml). The combined filtrate concentrated completely under reduced pressure. The residue was dissolved in isopropyl acetate (100 ml) and sequentially washed with 30% citric acid (2 x 50 ml) and water (50 ml). The combined aqueous layer was back-extracted with IPAc (25 ml) and saved for pyrrolidinylnorephidrine recovery. To the combined organic phase was added 12N HCl (4.1 ml). The resulting mixture was aged at 25-300C and then dried azeotropically and flushed with IPAc (2 x 25 ml). The slurry was aged for another 24 h at 25-300C and then filtered and washing was performed with cold IPAc (3 x 10 ml) and dried to afford 10 g of analytically pure (5>5-Chloro-α- (cyclopropylethynyl)-2-amino-α-(trifluoromethyl) benzene methanol hydrochloride as a white solid.
Example -3: Preparation of ιfi)-5-Chloro-α-(cyclopropylethynylV2-ammo-α- (trifluoromethyP benzene methanol.
A solution of chloromagnesium-cyclopropylacetylide (CPA-MgCl) was prepared by adding neat cyclopropyl acetylene (36.2 g, 0.548 mol) to a stirred solution of «-butyl magnesium chloride (2M solution in THF, 268.0 ml, 0.535 mol) at 0-50C. The solution was stirred for another 2h at 0-5 °C. In another dry flask, to anhydrous THF (300 ml) at 0-50C, NaH (57% dispersion in mineral oil, (44.0 g, 0.916 mol) was added slowly. The ice-bath was removed and the contents stirred at ambient temp for 30 min and cooled again to 0-50C. 2,2,2- Trifluoroethanol (43g, 0.429 mol), and (IR, 2S)-pyrrolidinyl norephidrine (135 g, 0.65 mol) were added and the resulting pale yellow solution was stirred at ambient temp for 60 min. Zinc chloride (73.1 g, 0.53mol) was added in four lots and stirred for 60 min at 25-30 0C. The solution of CPA-MgCl was then warmed to 25-30 °C and then transferred to the ephedrine zincate reagent, over 15 min., and the suspension was stirred for another 2h. 4-Chloro-2- trifluoroacetylaniline (100 g, 0.447 mol) was added in one portion to the reaction mixture and stirred for reaction completion.
The reaction mixture was diluted with toluene (300ml) and stirred for Ih and quenched into IM citric acid solution (1000ml) and stirred for 10 min. Toluene layer was separated and washed with water (2X500ml). The toluene layer was concentrated completely to give residue. The obtained residue was dissolved in methanol (300ml) and isolated by adding DM water (450ml).
Yield: 130 g

Claims

We claim;
1. A process to prepare organometallic complex comprising the steps of;
• Preparing the salts of chiral and/or achiral additives
• Adding metal halide to the above obtained salts and converting to chiral and/or achiral metal complex
• Adding Grignard reagent/ lithium reagent or Zinc reagent to the above chiral and/or achiral metal complex to form chiral organometal complex. (or)
• Adding terminal alkyne and a base to the above chiral metal complex to form chiral organometal complex.
2. The process as claimed in claim 1, wherein the salts of chiral and/or achiral additives are prepared by treating the chiral and/or achiral additives with a base .
3. The process as claimed in claim 2, wherein the base is selected from metal hydrides, metal alkoxides, metal hydroxides and organic bases
4. The process as claimed in claim 2, wherein the preferred base is a metal hydride.
5. The process as claimed in claim I5 wherein the metal halide is a transitional metal halide
6. The process as claimed in claim 5, wherein the most preferred metal halides are being
Zinc and copper halides.
7. A process to induce the enantioselectivity in procarbonyl compounds and their enantiomers of formula;
Figure imgf000012_0001
Wherein R1 is
C1 -C6 -alkyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F5 1), CF3, CN, NO2, NH2, NH(C1 -C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl), CON(Ci -C6 -alkyl)2) NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON(Ci -C6 -alkyl)2, CO2 -C1
-C6 -alkyl, C3 -C7 -cycloalkyl, or Ci -C6 -alkoxy; phenyl, biphenyl, or naphthyl, unsubstituted or substituted with one to four substituents selected from R3, R4, R5, and R6 ; R3, R4, R5, and R6 are independently: halo (Cl5 Br5 F5 1), CF3, CN, NO2, NH2, NH(C1 - C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl), CON(C1 -C6 -alkyl)2,
NHCONH2, NHCONH(C1 -C6 -alkyl), NHCON(Ci -C6 -alkyl)2, aryl, CO2 -C1 -C6 - alkyl, C1 -C6 -alkyl, C2 -C6 -alkenyl, C2 -C6 -alkynyl, C3 -C7 -cycloalkyl, or C1 -C6 - alkoxy, such that C1 -C6 -alkyl is unsubstituted or substituted with aryl, aryl is defined as phenyl, biphenyl, or naphthyl, unsubstituted or substituted with C1 -C6 -alkyl, Ci -C6 -alkoxy, NO2, or halo (Cl, Br, F, I);
R2 is: H,
C1 -C6 -alkyl, C2 -C6 - alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br5 F, I), CF3, CN, NO2, NH2, NH(C1 -C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl),
CON(C1 -C6 -alkyl)2, NHCONH2, NHCONH(Ci -C6 -alkyl), NHCON(C1 -C6 -alkyl)2, CO2 -C1 -C6 -alkyl, C3 -C7 -cycloalkyl, or Ci -C6 -alkoxy; C1 -C4 - perfluoroalkyl,
R is:
C1 -C6 -alkyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN5 NO2, NH2, NH(Ci -C6 -alkyl), N(Cj -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl), CON(C1 -C6 -alkyl)2, NHCONH2, NHCONH(C1 -C6 -alkyl), NHCON (C1 -C6 -alkyl)2, CO2 ~ C1 -C6 -alkyl, C3 -C7 -cycloalkyl, or C1 -C6 -alkoxy; Comprising the steps of:
• Preparing the salts of chiral and/or achiral additives
• Adding metal halide to the above obtained salts and converting to chiral and/or achiral metal complex • Adding the Grignard reagent/ lithium reagent or Zinc reagent to the above chiral and/or achiral metal complex to form chiral organometal complex.
• Adding the procarbonyl compounds to the chiral organometal complex
8. The process as claimed in claim 7, wherein the metal salts of chiral and/or achiral additives are prepared by treating the chiral and/or achiral additives with a base .
9. The process as claimed in claim 8, wherein the base is selected from metal hydrides, metal alkoxides, metal hydroxides and organic bases.
10. The process as claimed in claim 8, wherein the preferred base is a metal hydride.
11. The process as claimed in claim 7, wherein the metal halide is a transitional metal halide
12. The process as claimed in claim 11, wherein the most preferred metal halides are being
Zinc and copper halides.
13. A process for the preparation of an amino alcohol of formula:
Figure imgf000014_0001
Wherein
R3 is halo (Cl5 Br5 F5 1) R1 is amino or substituted amino
R2 is C1 -C6 -alkyl, C2 -C6 -alkenyl, or C2 -C6 -alkynyl, unsubstituted or mono- or di- substituted with a substituent selected from the group consisting of: halo (Cl, Br, F, I), CF3, CN, NO2, NH2, NH(C1 -C6 -alkyl), N(C1 -C6 -alkyl)2, CONH2, CONH(C1 -C6 -alkyl), CON(C1 -C6 -alkyl)2, NHCONH2, NHCONH(C, -C6 -alkyl), NHCON (C1 -C6 -alkyl)* CO2 - C1 -C6 -alkyl, C3 -C7 -cycloalkyl, or Ci -C6 -alkoxy; comprising the steps of:
• Adding slowly an alkanol and chiral additive to a base in an organic solvent
• Treating the above reaction mass with a metal halide to get chiral metal complex • Adding organometallic reagent of formula R2M, wherein M represents Li,
Zn or MgX; X is Cl, Br, I and F; to the chiral metal complex in a solvent and the suspension was stirred to get chiral organometal complex
• Mixing a carbonyl compound with the chiral organometal complex to give the chiral alcohol.
14. The process as claimed in claim 13, wherein the base is selected from metal hydrides, metal alkoxides, metal hydroxides and organic bases
15. The process as claimed in claim 14, wherein the preferred base is a metal hydride.
16. The process as claimed in claim 13, wherein the metal halide is a transitional metal halide
17. The process as claimed in claim 13, wherein the most preferred metal halides are being Zinc and copper halides.
PCT/IN2008/000476 2008-01-31 2008-07-30 An efficient process to induce enantioselectivity in procarbonyl compounds WO2009095931A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/667,985 US9156756B2 (en) 2008-01-31 2008-07-30 Efficient process to induce enantioselectivity in procarbonyl compounds
PL08808147T PL2235023T3 (en) 2008-01-31 2008-07-30 An efficient process to induce enantioselectivity in procarbonyl compounds
EP08808147.6A EP2235023B1 (en) 2008-01-31 2008-07-30 An efficient process to induce enantioselectivity in procarbonyl compounds
DK08808147.6T DK2235023T3 (en) 2008-01-31 2008-07-30 Effective method to induce enantioselectivity in PROCARBONYLFORBINDELSER
SI200831165T SI2235023T1 (en) 2008-01-31 2008-07-30 An efficient process to induce enantioselectivity in procarbonyl compounds
ES08808147.6T ES2449754T3 (en) 2008-01-31 2008-07-30 An efficient procedure to induce enantioselectivity in polycarbonyl compounds
US13/531,011 US9073817B2 (en) 2008-01-31 2012-06-22 Efficient process to induce enantioselectivity in procarbonyl compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN262CH2008 2008-01-31
IN262/CHE/2008 2008-01-31

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/667,985 A-371-Of-International US9156756B2 (en) 2008-01-31 2008-07-30 Efficient process to induce enantioselectivity in procarbonyl compounds
US13/531,011 Continuation-In-Part US9073817B2 (en) 2008-01-31 2012-06-22 Efficient process to induce enantioselectivity in procarbonyl compounds

Publications (2)

Publication Number Publication Date
WO2009095931A2 true WO2009095931A2 (en) 2009-08-06
WO2009095931A3 WO2009095931A3 (en) 2010-09-30

Family

ID=40913373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000476 WO2009095931A2 (en) 2008-01-31 2008-07-30 An efficient process to induce enantioselectivity in procarbonyl compounds

Country Status (10)

Country Link
US (1) US9156756B2 (en)
EP (1) EP2235023B1 (en)
CN (1) CN101497573B (en)
CY (1) CY1115209T1 (en)
DK (1) DK2235023T3 (en)
ES (1) ES2449754T3 (en)
PL (1) PL2235023T3 (en)
SI (1) SI2235023T1 (en)
WO (1) WO2009095931A2 (en)
ZA (1) ZA200806473B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011000532A2 (en) 2009-07-03 2011-01-06 Archimica Gmbh Method for the enantioselective addition of organometallic carbon nucleophiles to trifluoromethyl ketones and use of the method in the synthesis of hiv reverse transcriptase inhibitors
CN102372533A (en) * 2011-11-01 2012-03-14 浙江新华制药有限公司 Unsymmetrical addition method of fluoroalkyl contained arone using tartaric acid derivative catalytic terminal alkyne zinc reagent
CN102617370A (en) * 2012-03-05 2012-08-01 浙江江北药业有限公司 Preparation method of (S)-5-chloro-alpha-(cyclopropylacetylene)-2-(((4-methoxyl phenyl) methyl)amino)-alpha-(trifluoromethyl) phenylcarbinol
CN103833560A (en) * 2013-03-25 2014-06-04 安徽贝克联合制药有限公司 Preparation method of (S)-5-chloro-alpha-cyclopropinyl-2-amino-alpha-trifluoromethyl phenylcarbinol
US10214480B2 (en) 2015-02-15 2019-02-26 Shanghai Desano Pharmaceutical Co., Ltd. Synthesis process for chiral cyclopropyl ethynyl tertiary alcohol compound
CN115010682A (en) * 2022-06-24 2022-09-06 盐城迪赛诺制药有限公司 Method for substituting inorganic acid for organic acid in acidification process of efavirenz key intermediate
CN115197075A (en) * 2021-11-18 2022-10-18 盐城迪赛诺制药有限公司 Preparation method of efavirenz key intermediate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073817B2 (en) * 2008-01-31 2015-07-07 Laurus Labs Private Limited Efficient process to induce enantioselectivity in procarbonyl compounds
CN111548317A (en) * 2020-04-28 2020-08-18 苏州纪元康生物科技有限公司 Efavirenz synthesis method and method for preparing intermediate thereof
CN115073310A (en) * 2022-07-05 2022-09-20 盐城迪赛诺制药有限公司 Method for reducing specific impurities in efavirenz key intermediate mother liquor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0981520A1 (en) 1997-05-16 2000-03-01 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
EP1614672A1 (en) 2003-04-04 2006-01-11 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences An amino alcohol ligand and its use in preparation of chiral proparglic tertiary alkohols and tertiary amines via enantioselective additon reaction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5633405A (en) * 1995-05-25 1997-05-27 Merck & Co., Inc. Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one
DE19812480A1 (en) * 1998-03-21 1999-09-23 E B S Gmbh Ink-jet printer for labeling goods
US6586644B2 (en) * 2001-10-05 2003-07-01 Erick M. Carreira Process for producing optically active propargyl alcohols
WO2011000532A2 (en) 2009-07-03 2011-01-06 Archimica Gmbh Method for the enantioselective addition of organometallic carbon nucleophiles to trifluoromethyl ketones and use of the method in the synthesis of hiv reverse transcriptase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0981520A1 (en) 1997-05-16 2000-03-01 Merck & Co., Inc. Efficient enantioselective addition reaction using an organozinc reagent
EP1614672A1 (en) 2003-04-04 2006-01-11 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences An amino alcohol ligand and its use in preparation of chiral proparglic tertiary alkohols and tertiary amines via enantioselective additon reaction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2235023A2

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011000532A2 (en) 2009-07-03 2011-01-06 Archimica Gmbh Method for the enantioselective addition of organometallic carbon nucleophiles to trifluoromethyl ketones and use of the method in the synthesis of hiv reverse transcriptase inhibitors
WO2011000532A3 (en) * 2009-07-03 2011-05-05 Archimica Gmbh Method for the enantioselective addition of organometallic carbon nucleophiles to trifluoromethyl ketones and use of the method in the synthesis of hiv reverse transcriptase inhibitors
CN102372533A (en) * 2011-11-01 2012-03-14 浙江新华制药有限公司 Unsymmetrical addition method of fluoroalkyl contained arone using tartaric acid derivative catalytic terminal alkyne zinc reagent
CN102617370A (en) * 2012-03-05 2012-08-01 浙江江北药业有限公司 Preparation method of (S)-5-chloro-alpha-(cyclopropylacetylene)-2-(((4-methoxyl phenyl) methyl)amino)-alpha-(trifluoromethyl) phenylcarbinol
CN103833560A (en) * 2013-03-25 2014-06-04 安徽贝克联合制药有限公司 Preparation method of (S)-5-chloro-alpha-cyclopropinyl-2-amino-alpha-trifluoromethyl phenylcarbinol
CN103833560B (en) * 2013-03-25 2016-05-25 安徽贝克联合制药有限公司 (S) preparation method of-5-chloro-α-cyclopropyne base-2-amino-α-trifluoromethyl benzyl alcohol
US10214480B2 (en) 2015-02-15 2019-02-26 Shanghai Desano Pharmaceutical Co., Ltd. Synthesis process for chiral cyclopropyl ethynyl tertiary alcohol compound
CN115197075A (en) * 2021-11-18 2022-10-18 盐城迪赛诺制药有限公司 Preparation method of efavirenz key intermediate
CN115010682A (en) * 2022-06-24 2022-09-06 盐城迪赛诺制药有限公司 Method for substituting inorganic acid for organic acid in acidification process of efavirenz key intermediate

Also Published As

Publication number Publication date
ES2449754T3 (en) 2014-03-21
US9156756B2 (en) 2015-10-13
WO2009095931A3 (en) 2010-09-30
SI2235023T1 (en) 2014-04-30
DK2235023T3 (en) 2014-03-10
US20100286408A1 (en) 2010-11-11
PL2235023T3 (en) 2014-07-31
ZA200806473B (en) 2009-04-29
EP2235023B1 (en) 2013-12-11
CN101497573B (en) 2013-09-18
EP2235023A4 (en) 2011-09-07
EP2235023A2 (en) 2010-10-06
CN101497573A (en) 2009-08-05
CY1115209T1 (en) 2017-01-04

Similar Documents

Publication Publication Date Title
US9156756B2 (en) Efficient process to induce enantioselectivity in procarbonyl compounds
EP1276745B1 (en) Ruthenium-diphosphine complexes and their use as catalysts
US20040106818A1 (en) Process for the preparation of cyclohexanol derivatives
JP4464388B2 (en) Phosphine compound, intermediate, palladium complex, and method for producing unsaturated compound using the complex
US20190233452A1 (en) Process
WO2001066248A2 (en) C-c and c-n coupling catalyst comprising transition metal and carbene
JPH08253486A (en) Production of pentafluorophenyl compound
CN111032668B (en) Optically active 2,3-bisphosphinylpyrazine derivative, process for producing the same, transition metal complex, and process for producing organoboron compound
EP2752402B1 (en) Production method for 2-alkenylamine compound
WO2015122502A1 (en) Method for producing optically active compound, and novel metal-diamine complex
US10428098B2 (en) Processes for preparing and using ruthenium and osmium complexes
US20060135788A1 (en) Process for obtaining cizolirtine and its enantiomers
WO2009122408A1 (en) STABLE C - (sup3) - CYCLOMETALATED PINCER COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS
JP6000256B2 (en) Method for producing 2-alkenylamine compound
CN109776400B (en) Preparation method of (R) -phenyl (pyridine-2-yl) methanol derivative
US6184404B1 (en) Process for the selective alkylation of aldehydes by means of organozinc compounds
CN101837303A (en) Novel nickel catalyst and preparation method and application thereof
JP5540117B2 (en) Method for allylating and vinylating aryl halides, heteroaryl halides, alkyl halides, and halogenated alkenes using transition metal catalysis
US6515180B1 (en) Method for the catalytic, symmetric disubstitution of carboxylic acid amides with grignard reagents
CN109096109B (en) Synthesis method of 2-butenoic ester
KR101654787B1 (en) Catalyst Composition Comprising Palladium Ketoiminate Complex and Preparation Method for Cross-Coupling Compound Using the Composition
JP2023546688A (en) Selective alkylation of cyclopentadiene
JP2014024777A (en) Method for producing polycyclic aromatic compound having halogen atom
JP2023500501A (en) Novel transition metal catalyst
CN117756622A (en) Preparation method of key intermediate of sabatier

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08808147

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12667985

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2008808147

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE